We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER: Tirzepatide Could Be Cost-Effective in Type 2 Diabetes at $5,500 to $7,500 Annually
ICER: Tirzepatide Could Be Cost-Effective in Type 2 Diabetes at $5,500 to $7,500 Annually
Tirzepatide, Eli Lilly’s potential dual-molecule blockbuster for type 2 diabetes (T2D), should be priced at $5,500 to $7,500 per year to be a cost-effective therapeutic option, according to the Institute for Clinical and Economic Review (ICER).